• BIRB 796: Reframing p38α Inhibition

  2026-08-19

  BIRB 796 (Doramapimod) offers translational researchers a highly selective allosteric approach to p38α MAPK inhibition. This thought-leadership perspective connects its signaling biology, assay design, formulation considerations, inflammatory disease evidence, and emerging insights into inhibitor-directed dephosphorylation.

• O6-Benzylguanine: MGMT Inhibitor Workflows

  2026-08-18

  O6-Benzylguanine provides a direct chemical route to MGMT inhibition, helping researchers test why alkylating agents fail in resistant cancer models. This practical guide connects stock preparation, combination-treatment design, DNA-damage readouts, and the AP-2α/MGMT findings reported in recurrent glioblastoma.

• Dabigatran Etexilate: Oral Thrombin Inhibition

  2026-08-18

  This review examines how dabigatran etexilate established oral direct thrombin inhibition as a practical alternative to therapies requiring injections or intensive INR monitoring. The reference paper integrates pharmacology, pharmacokinetics, clinical efficacy, safety, and dosing considerations across venous thromboembolism and nonvalvular atrial fibrillation.

• Cediranib (AZD2171) for VEGFR Assays

  2026-08-17

  Cediranib (AZD2171) enables mechanism-focused studies of VEGFR signaling, angiogenesis, and downstream PI3K/Akt/mTOR signaling inhibition. Its greatest experimental value emerges when target-proximal phosphorylation data are paired with separate measurements of growth arrest and cell death.

• Substance P: Applied Tachykinin Workflows

  2026-08-17

  Build more reproducible pain transmission research and neuroimmune assays with a water-soluble Substance P peptide designed for controlled receptor stimulation. This guide combines practical preparation and response-measurement workflows with a data-quality strategy adapted from fluorescence-based interference research.

• TPCA-1: Mapping IKK-2 to Inflammatory Cell Fate

  2026-08-16

  TPCA-1 is a highly selective IKK-2 inhibitor for dissecting NF-κB-driven cytokine programs, inflammatory disease biology, and the boundary between inflammatory transcription and RIPK1-regulated cell death.

• TAK-242 (Resatorvid): From TLR4 Biology to Translation

  2026-08-15

  TAK-242 (Resatorvid) offers translational researchers a selective way to interrogate TLR4-driven inflammation. By connecting macrophage assays with evidence from a mouse posttraumatic epilepsy model, this article outlines how TLR4 signaling pathway modulation can move from molecular mechanism to better-designed neuroinflammation research.

• Ruxolitinib phosphate: JAK/STAT Research Workflows

  2026-08-14

  Ruxolitinib phosphate (INCB018424) enables controlled JAK1/JAK2 inhibition across cytokine, autoimmune, hematologic, and solid-tumor models. This workflow-centered guide connects pathway pharmacology with apoptosis, pyroptosis, and mitochondrial-dynamics assays while emphasizing practical controls and troubleshooting.

• Psora 4 for Reproducible Kv1.3 Assays

  2026-08-14

  This scenario-based guide explains how Psora 4, SKU B7659, can support mechanistic T-cell proliferation, cytotoxicity, and Ca2+ signaling studies. It covers selectivity, KCNE4-dependent pharmacology, formulation, data interpretation, and practical product-selection criteria.

• MLKL–Lysosome Signaling in Necroptosis

  2026-08-13

  The reference study identifies MLKL polymerization-induced lysosomal membrane permeabilization as a critical execution step in necroptosis. By combining live-cell imaging with cathepsin B perturbation, the authors show that lysosomal rupture and cytosolic cathepsin B release occur before plasma membrane failure and promote cell death.

• TMAO Activates PERK in a Zebrafish NAFLD Model

  2026-08-13

  The reference study shows that dietary trimethylamine N-oxide (TMAO) can directly produce steatosis, inflammation, liver injury, and fibrosis in zebrafish, extending associations between circulating TMAO and non-alcoholic fatty liver disease. Evidence from zebrafish, HepG2 cells, and hepatic stellate cells identifies PERK signaling as a mechanistically relevant component of TMAO-associated liver pathology, while also defining important limits for translation.

• MK-0812 and the Gut–Liver Inflammation Axis

  2026-08-12

  MK-0812 is a selective CCR2 antagonist for resolving how monocyte trafficking contributes to gut–liver inflammation. This article connects functional CCR2 blockade with the compartment-specific mechanisms identified in intestinal TM6SF2 research and offers an assay-focused framework for interpretation.

• Bazedoxifene: SERM Mechanism and Research Evidence

  2026-08-12

  Bazedoxifene is a third-generation selective estrogen receptor modulator with tissue-selective activity relevant to postmenopausal osteoporosis and estrogen receptor signaling research. Evidence also supports antimalarial repurposing research through inhibition of Plasmodium growth and hemozoin formation, but this application remains preclinical.

• Tofacitinib: A Causal Assay Framework for JAK Biology

  2026-08-11

  Tofacitinib and CP-690550 offer a powerful way to dissect cytokine signaling, lymphocyte behavior, and macrophage state transitions. This article develops a causal assay framework that separates proximal JAK/STAT effects from downstream immunometabolic readouts in rheumatoid arthritis research.

• Early Life Adversity, Oxytocin, and Innate Defense

  2026-08-11

  This 2026 Communications Biology study identifies a circuit-level mechanism by which early life adversity impairs looming-evoked innate defensive behavior in mice. Its experiments link social deprivation to reduced oxytocin receptor expression in the superior colliculus, implicate hypothalamic oxytocin projections, and show that intranasal oxytocin can partially ameliorate the behavioral deficit.

544 records 7/37 page Previous Next First page 上5页 678910 下5页 Last page